Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG

Preoperative Colchicine, Dronedarone Or Amiodarone for Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG; A Comparative Study

Atrial fibrillation in the postoperative period of myocardial revascularization surgery (AF-POMR) occurs in 10% to 65% of patients, increasing morbidity and mortality after surgery. is associated with an increase in hospital length of stay, and, thus, in costs,and can cause serious clinical complications, such as hypotension, heart failure, stroke and other thromboembolic disorders.Although not completely understood, the electrophysiological mechanism of AF-POMR is believed to be reentry.

Study Overview

• Status: Unknown
• Conditions: Postoperative Atrial Fibrillation
• Intervention / Treatment: Drug: Colchicine; Drug: Dronedarone; Drug: Amiodarone

Detailed Description

Aim of the study The aim of this work is to study the effect of preoperative Colchicine, Dronedarone or Amiodarone for prophylaxis against postoperative atrial fibrillation in patients undergoing on-pump CABG.

Patients and Methods

Type and site of the study:

This randomized double blinded clinical study will be carried out at Beni-Suef university hospital, after approval by the department of Anesthesiology, Pain management and Surgical ICU, the local ethics and research committee and other involved departments, faculty of medicine, Beni-Suef University.

Study population:

The study population will include inpatients of the cardiothoracic department scheduled for CABG surgery, both sex, selected randomly according to American Society of Anesthesiologists(ASA) grade II and III, between the ages of 40 -60ears.

Exclusion criteria:.

• Liver dysfunction, pregnancy.
• History of allergic reaction to any drug used in this study.
• Emergency procedure
• Preoperative dialysis
• A.F.
• Patients on antiarrhythmic medications

Sample size estimation:

As considered the primary outcome, sample size calculation was done using the comparison of the rate of occurrence of postoperative AF in cases undergoing on-pump CABG pretreated with colchicine, dronedarone or amiodarone. As previously published 19 , the rate of postoperative AF among amiodarone group was 25%, while in colchicine, it was 7% 20. investigators assumed that dronedarone treatment will differ about 20% from amiodarone and selected the least excepted difference to do the calculation. Therefore, the calculation was done based on comparing 2 proportions from independent samples using Chi test, the α-error level was fixed at 0.05 and the power was set at 80%.

Accordingly, the optimum sample size should be 48 cases in each arm. Sample size calculation was done using PS Power and Sample Size Calculations software, version 3.0.11 for MS Windows (William D. Dupont and Walton D. Vanderbilt, USA).

Sampling Technique:

The patients will be randomly divided into three groups, as follows: Group c: Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge ; Group D: Dronedarone (200 mg twice daily starting from day before operation till 5 days after) ; Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery Randomization assignment of patients to Groups C, D and A will be performed with a list of random numbers generated by a computer program's random function. The allocation into the groups and the preparation of the study drug will be performed by an individual who as unrelated to the study. Personnel, patients, and the individual participating in the data collection and data analysis will be blinded to the treatment assignments.

Anesthesia Management The patients will be evaluated preoperatively 1 day before surgery. Electrocardiogram (ECG), pulse oximetry, cannulation of the invasive arterial pressure (20 gauge) from the left radial artery, and peripheral venous access (18 gauge) from the right arm will be inserted into the patient, who will be taken to the operating room on the day of the surgery. After induction of anesthesia and intubation, an 8F central venous catheter will be inserted from the right internal jugular vein. Midazolam (0.05 mg/kg), propofol (2 mg/kg), fentanyl (5 mcg/kg), and rocuronium (0.6 mg/kg) will be used for the induction of anesthesia. Anesthesia will be maintained with a mixture of 2% sevoflurane, 60% oxygen, and 40% air.

All patients will be ventilated with positive pressure. Ventilation parameters will be set as a tidal volume of 8ml/kg and a respiratory rate of 10-12/min, which will be assessed by arterial blood gases. All patients will receive 500 ml ringer lactat before the induction of anesthesia. Thereafter, IV ringer lactate solution will be infused to keep the central venous pressure (CVP) at 10-12 mmHg.

Cardiopulmonary Bypass Management Before cannulation for CPB, 3 mg/kg of heparin will be administered for all patients. When the activated coagulation time will be > 400/sec, it will be passed to the pump.

Nonpulsatile CPB flow rates of 2-2.4 L/min/m2 will be applied, and the mean arterial pressure (MAP) will be kept at 50-60 mmHg. Hematocrit concentration will be maintained at 25-28%. Moreover, mild hypothermia (28-30°C) will be reached during CPB. Myocardial protection will be achieved with intermittent antegradecardtemperature of 37°C will be achieved after surgery, and the patient will be removed from CPB. Following this, coagulation will be provided with protamine; once hemodynamic stabilization (MAP 70-90 mmHg) will be achieved, patients will be brought to the intensive care unit.

Data Collection Methods:

The following parameters will be evaluated and recorded by senior anesthesiologist unaware of the study protocol:

• Demographic data (age, sex, and weight)
• Perioperative data (operation time, cross-clamp time, EF ).
• Post bypass and post operative AF
• Hospital stay and death

Statistical analysis Continuous variables will be summarized as mean ± SD and categorical variables Will be expressed as proportion (%). Univariate analyses will be performed by chi-square, student's t-test, Fisher exact test, Mann Whitney test and One-way ANOVA (will be used for comparison between the three groups). SPSS for Windows (version 17; SPSS Inc., Chicago, IL., USA) will be used for statistical analysis. Results will be considered significant if P values are less than 0.05p

• Study Type: Interventional
• Enrollment (Anticipated): 48
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: Doaa A Rashwan, MD; Phone Number: 00201011270763; Email: doaa_rashwan@hotmail.com
• Study Contact Backup: Name: Belal Y Mohammed, Msc; Phone Number: 0020124138153; Email: byahia37@gmail.com

Study Locations

• Egypt
  • Banī Suwayf, Egypt, 11391
    • Recruiting
    • Faculty of Medicine, Beni-suef University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 60 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

The study population will include inpatients of the cardiothoracic department scheduled for CABG surgery, both sex, selected randomly according to American Society of Anesthesiologists(ASA) grade II and III

Exclusion Criteria:

• - Liver dysfunction, pregnancy.
• History of allergic reaction to any drug used in this study.
• Emergency procedure
• Preoperative dialysis
• A.F.
• Patients on antiarrhythmic medications

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: colchicine; Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge	Drug: Colchicine; Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge; Other Names: amiodarone, dorendarone
ACTIVE_COMPARATOR: Dronedarone; Dronedarone (200 mg twice daily starting from day before operation till 5 days after)	Drug: Dronedarone; Dronedarone (200 mg twice daily starting from day before operation till 5 days after); Other Names: amiodarone,colchicine
ACTIVE_COMPARATOR: amiodarone; amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery	Drug: Amiodarone; Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery; Other Names: colchicine ,dronedarone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AF	incidence of AF	change from baseline rhythm at 6 days

Collaborators and Investigators

• Sponsor: doaa rashwan
• Investigators: Principal Investigator: belal Y Mohammed, Msc, Faculty of Medicine Beni-Suef University

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 3, 2019
• Primary Completion (ANTICIPATED): April 10, 2020
• Study Completion (ANTICIPATED): April 10, 2020

Study Registration Dates

• First Submitted: April 1, 2019
• First Submitted That Met QC Criteria: April 4, 2019
• First Posted (ACTUAL): April 5, 2019

Study Record Updates

• Last Update Posted (ACTUAL): April 5, 2019
• Last Update Submitted That Met QC Criteria: April 4, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Atrial Fibrillation; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Vasodilator Agents; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Membrane Transport Modulators; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Sodium Channel Blockers; Cytochrome P-450 CYP2D6 Inhibitors; Gout Suppressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Potassium Channel Blockers; Colchicine; Amiodarone; Dronedarone
• Other Study ID Numbers: FMBSURECS/31032019/Mohammed

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: the protocol
• IPD Sharing Time Frame: after registration for ever
• IPD Sharing Access Criteria: on the web page
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No